Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C
-
- Arase Yasuji
- Department of Hepatology, Toranomon Hospital
-
- Suzuki Fumitaka
- Department of Hepatology, Toranomon Hospital
-
- Suzuki Yoshiyuki
- Department of Hepatology, Toranomon Hospital
-
- Akuta Norio
- Department of Hepatology, Toranomon Hospital
-
- Kawamura Yusuke
- Department of Hepatology, Toranomon Hospital
-
- Kobayashi Masahiro
- Department of Hepatology, Toranomon Hospital
-
- Hosaka Tetsuya
- Department of Hepatology, Toranomon Hospital
-
- Sezaki Hitomi
- Department of Hepatology, Toranomon Hospital
-
- Yatsuji Hiromi
- Department of Hepatology, Toranomon Hospital
-
- Kobayashi Mariko
- Hepatic Research Unit, Toranomon Hospital
-
- Ikeda Kenji
- Department of Hepatology, Toranomon Hospital
-
- Kumada Hiromitsu
- Department of Hepatology, Toranomon Hospital
この論文をさがす
抄録
Objective The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C.<br> Methods Inclusion criteria were HCV-genotype 1b and serum HCV RNA level of >100 KIU/ml. Six hundred and twelve patients were received combination therapy and enrolled in this non-randomized prospective cohort study. Patients were monitored until the discontinuation of combination therapy based on treatment-related side effects. The percentage of each medication actually taken during treatment was calculated.<br> Results Sixty-eight patients were stopped the combination therapy due to side effects. The cumulative discontinuation rate due to side effects of therapy was 8.4% at 0.5 year and 14.9% at one year. Discontinuation rate due to side effects was high with statistically significant in the following cases: 1) patients ≥65 years, 2) patients who had diabetes. Sustained viral response (SVR) was 17.6% (12/68) in the discontinuation group. In the discontinuation group, when the percentage of both peginterferon and ribavirin actually taken during treatment was ≥60%, SVR was 31% (9/29). On the other hand, when the percentage of each medication actually taken during treatment was <60%, SVR was 7.7% (3/39). In the discontinuation group, patients with adherence of >60% to the total of scheduled dose tended to have a high SVR compared to those with ≤60% adherence to the total of scheduled dose.<br> Conclusion In combination therapy, patient age and complications of patient are important factors contributing to the safety. In the discontinuation group, patients with adherence of >60% to the total of scheduled dose tend to have a high SVR.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 46 (22), 1827-1832, 2007
一般社団法人 日本内科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679849031424
-
- NII論文ID
- 130000075920
-
- ISSN
- 13497235
- 09182918
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可